Meeting
2023 ASCO Genitourinary Cancers Symposium
Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Mark N. Stein
Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
Mark N. Stein , Benjamin A. Teply , Usama Gergis , Donald Strickland , Joseph Senesac , Henri Bayle , Monica Sheila Chatwal , Mehmet Asim Bilen , Walter Michael Stadler , Ecaterina Elena Dumbrava
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02744287
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 140)
DOI
10.1200/JCO.2023.41.6_suppl.140
Abstract #
140
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Susan F. Slovin
Poster
2023 ASCO Annual Meeting
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
First Author: Changqing Xie